Demographics and baseline characteristics of study population
| Parameter . | Result . | % . |
|---|---|---|
| Median age at diagnosis of iron overload (range), y | 31.5 (2-70) | |
| Sickle cell disease | 30 (11-65) | |
| Beta-thalassemia major | 24.5 (2-61) | |
| Other congenital hemolytic anemias∗ | 42 (18-70) | |
| Female, n (%) | 97 | 57 |
| Ethnicities | ||
| Black | 79 | 46 |
| White | 47 | 28 |
| Hispanic or Latino | 12 | 7 |
| Asian | 19 | 11 |
| Other | 8 | 5 |
| Unknown | 5 | 3 |
| Deceased, n (%) | 30 | 18 |
| Sickle cell disease, n (%) | 105 | 62 |
| Beta-thalassemia major | 30 | 18 |
| Other congenital hemolytic anemias∗ | 35 | 21 |
| Mean peak ferritin | 6659 | |
| Diabetes, n (%) | 44 | 26 |
| Heart disease, n (%) | 37 | 22 |
| Malignancy, n (%) | 14 | 8 |
| Bone mineral disease, n (%) | 46 | 27 |
| Chelator history | ||
| Deferasirox | 61 | 36 |
| Deferoxamine | 15 | 9 |
| Deferiprone | 8 | 5 |
| Dual chelation | 4 | 2 |
| Unknown | 103 | 48 |
| Parameter . | Result . | % . |
|---|---|---|
| Median age at diagnosis of iron overload (range), y | 31.5 (2-70) | |
| Sickle cell disease | 30 (11-65) | |
| Beta-thalassemia major | 24.5 (2-61) | |
| Other congenital hemolytic anemias∗ | 42 (18-70) | |
| Female, n (%) | 97 | 57 |
| Ethnicities | ||
| Black | 79 | 46 |
| White | 47 | 28 |
| Hispanic or Latino | 12 | 7 |
| Asian | 19 | 11 |
| Other | 8 | 5 |
| Unknown | 5 | 3 |
| Deceased, n (%) | 30 | 18 |
| Sickle cell disease, n (%) | 105 | 62 |
| Beta-thalassemia major | 30 | 18 |
| Other congenital hemolytic anemias∗ | 35 | 21 |
| Mean peak ferritin | 6659 | |
| Diabetes, n (%) | 44 | 26 |
| Heart disease, n (%) | 37 | 22 |
| Malignancy, n (%) | 14 | 8 |
| Bone mineral disease, n (%) | 46 | 27 |
| Chelator history | ||
| Deferasirox | 61 | 36 |
| Deferoxamine | 15 | 9 |
| Deferiprone | 8 | 5 |
| Dual chelation | 4 | 2 |
| Unknown | 103 | 48 |
Represents individuals with beta-thalassemia intermedia, hereditary spherocytosis, hemoglobin E disease, congenital dyserythropoietic anemia, hemoglobin H disease, pyruvate kinase deficiency, and glucose-6-phosphate dehydrogenase deficiency.